Company intelligence / Profile preview
SparX Biotech
Mount Prospect, Illinois, United Statessparxbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
SparX Biopharmaceutical is in Phase 1 clinical trials for multiple bispecific and antibody-drug conjugate (ADC) programs, including the first-in-class anti-LILRB2/PD-L1 bispecific antibody (SPX-303), targeting solid tumors and demonstrating promising preclinical and early clinical data for immune system activation against cancer[2][6][8].
- Therapeutic areas
- OncologyNeurology
- Modalities
- Bispecific antibodyMonoclonal antibodyAntibodySynthetic peptideAntibody-drug conjugateSmall moleculeCAR-T cell therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Mitsubishi Tanabe Pharma America[7]
Beyond the preview
Go deeper on SparX Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SparX Biotech.